Australia markets closed

    +1.00 (+0.01%)
  • ASX 200

    +1.70 (+0.02%)

    -0.0041 (-0.60%)
  • OIL

    +0.22 (+0.24%)
  • GOLD

    -8.20 (-0.46%)

    -2,962.42 (-8.69%)
  • CMC Crypto 200

    -33.15 (-6.12%)

    -0.0002 (-0.03%)

    +0.0090 (+0.81%)
  • NZX 50

    -129.53 (-1.10%)

    -265.86 (-1.97%)
  • FTSE

    +8.52 (+0.11%)
  • Dow Jones

    -295.75 (-0.87%)
  • DAX

    -152.89 (-1.12%)
  • Hang Seng

    +9.12 (+0.05%)
  • NIKKEI 225

    -11.77 (-0.04%)

Interleukin Inhibitors Global Market Report 2021: Focus on IL-17, IL-23, IL-1, IL-5, IL-6, Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, Asthma, Inflammatory Bowel Disease -

·4-min read

DUBLIN, December 08, 2021--(BUSINESS WIRE)--The "Interleukin Inhibitors Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to's offering.

The global interleukin inhibitors market is expected to grow from $17.73 billion in 2020 to $19.88 billion in 2021 at a compound annual growth rate (CAGR) of 12.1%. The market is expected to reach $32 billion in 2025 at a CAGR of 13%.

Major players in the interleukin inhibitors market are Sanofi, GlaxoSmithKline, Novartis, Johnson & Johnson, Roche, Eli Lilly, AstraZeneca, Teva Pharmaceutical, and Regeneron Pharmaceuticals.

The interleukin inhibitors market consists of the sales of interleukin inhibitors such as interleukin -1, interleukin -5, interleukin -6, interleukin -17, interleukin 23, by companies that manufacture them. These interleukin inhibitors are used for the treatment of autoimmune and inflammatory disorders such as psoriasis, psoriatic arthritis, rheumatoid arthritis, asthma, and inflammatory bowel disease

The interleukins inhibitors market covered in this report is segmented by type into IL-17, IL-23, IL-1, IL-5, IL-6, others. It is also segmented by application into psoriasis, psoriatic arthritis, rheumatoid arthritis, asthma, inflammatory bowel disease, others and by application into hospital pharmacies, retail pharmacies, online pharmacies.

High costs associated with biological therapy are hampering the interleukin inhibitors market. Biologic treatment that has revolutionized the care of psoriasis patients is expensive than the other treatments. The total annual cost ranged from $2,077 to US $13,132 for psoriasis and from $10,924 to $17,050 for psoriatic arthritis, per patient. As of 2020, biologics treatment cost was around $10,000 to $30,000 per year. The higher price of biologics and low healthcare expenditure in developing countries is, therefore, likely to hinder the market growth.

An increase in the number of investigational drugs for inflammatory diseases such as psoriasis, arthritis, and inflammatory bowel disease will drive the interleukin inhibitors market. Inhibitors of interleukin decrease the actions of the inflammatory cytokines, stimulate innate immune responses preventing damage to the host, and maintain normal tissue homeostasis.

There are 48 molecules under investigation for the treatment of inflammatory diseases such as psoriasis and psoriatic arthritis. Among these, 20 molecules are in Phase III clinical trials. These growing numbers of pipeline drugs will drive the interleukin inhibitor market upon approval.

Patent expiry of biologic drugs is opening opportunities for biosimilar drugs, which are a cheap alternative. Major companies in the interleukins sector are focusing on developing biosimilars for interleukin inhibitors.

For instance, biosimilars for IL inhibitors such as canakinumab (Ilaris), ustekinumab (Stelara), tocilizumab (Actemra), and secukinumab (Cosentyx) among others are in development by Mabpharm, NeuClone Pharmaceuticals Ltd, Gedeon Richter, and Bio-Thera Solutions, respectively.

Despite the clinical benefits associated with the use of biologics in psoriasis and other autoimmune diseases, many patients are not treated with biologic therapy, and access to treatment may be limited for several reasons including higher treatment costs. This factor coupled with rapid advances in biotechnology and analytical sciences, which ensure comparability of biosimilars to biologic drugs, drive the trend for biosimilars.

Key Topics Covered:

1. Executive Summary

2. Interleukin Inhibitors Market Characteristics

3. Interleukin Inhibitors Market Trends and Strategies

4. Impact Of COVID-19 On Interleukin Inhibitors

5. Interleukin Inhibitors Market Size and Growth

5.1. Global Interleukin Inhibitors Historic Market, 2015-2020, $ Billion

5.1.1. Drivers Of the Market

5.1.2. Restraints On the Market

5.2. Global Interleukin Inhibitors Forecast Market, 2020-2025F, 2030F, $ Billion

5.2.1. Drivers Of the Market

5.2.2. Restraints On the Market

6. Interleukin Inhibitors Market Segmentation

6.1. Global Interleukin Inhibitors Market, Segmentation by Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

  • IL-17

  • IL-23

  • IL-1

  • IL-5

  • IL-6

  • Others

6.2. Global Interleukin Inhibitors Market, Segmentation by Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

  • Psoriasis

  • Psoriatic Arthritis

  • Rheumatoid Arthritis

  • Asthma

  • Inflammatory Bowel Disease

  • Others

6.3. Global Interleukin Inhibitors Market, Segmentation by Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

  • Hospital Pharmacies

  • Retail Pharmacies

  • Online Pharmacies

7. Interleukin Inhibitors Market Regional and Country Analysis

7.1. Global Interleukin Inhibitors Market, Split by Region, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

7.2. Global Interleukin Inhibitors Market, Split by Country, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

Companies Mentioned

  • Sanofi

  • GlaxoSmithKline

  • Novartis

  • Johnson & Johnson

  • Roche

  • Eli Lilly

  • AstraZeneca

  • Teva Pharmaceutical

  • Regeneron Pharmaceuticals

  • Bausch Health

For more information about this report visit

View source version on

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting